Davis Polk advised Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC as joint book-running managers of the several underwriters in connection with the SEC-registered primary offering of 4,197,500 shares of common stock of Chimerix, Inc. The total gross proceeds to Chimerix, Inc. totaled approximately $121.7 million. The common stock is listed on the NASDAQ Global Market under the symbol “CMRX.”

Based in Durham, North Carolina, Chimerix, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. Chimerix, Inc.’s lead compound, brincidofovir (CMX001), is currently enrolling a Phase 3 clinical trial for the prevention of cytomegalovirus and other viruses in hematopoetic cell transplant recipients, and is in the pilot portion of a Phase 3 trial for the treatment of life threatening adenovirus infections. In addition, Chimerix, Inc. has an active discovery program leveraging its lipid technology and the Chimerix Chemical Library, both focusing on viral targets in areas of high unmet medical need.  

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Marcel Fausten. Associate Jansen A. S. Thurmer provided intellectual property advice. Counsel Craig A. Phillips and associate Kay Ng provided tax advice. The environmental team included counsel Loyti Cheng and associate Michael Comstock. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.